Wave Life Sciences Ltd. (WVE)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Revenue | 8,699 | 9,175 | -7,676 | |
| Research and development | 43,469 | 40,622 | 41,197 | |
| General and administrative | 17,989 | 18,357 | 15,042 | |
| Total operating expenses | 61,458 | 58,979 | 56,239 | |
| Loss from operations | -52,759 | -49,804 | -63,915 | |
| Investment income, interest and dividend, total | - | - | 1,798 | |
| Other income (expense), net | -82 | 51 | 337 | |
| Interest income | 2,372 | 2,875 | - | |
| Total other income, net | 2,290 | 2,926 | 2,135 | |
| Loss before income taxes | -50,469 | -46,878 | -61,780 | |
| Income tax benefit (provision) | - | - | - | |
| Net loss | -50,469 | -46,878 | -61,780 | |
| Foreign currency translation | 43 | 58 | 120 | |
| Comprehensive loss | -50,426 | -46,820 | -61,660 | |
| Earnings per share, basic, total | -0.31 | -0.29 | -0.47 | |
| Earnings per share, diluted, total | -0.31 | -0.29 | -0.47 | |
| Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders basic | 163,987,640 | 162,527,026 | 132,563,467 | |
| Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders diluted | 163,987,640 | 162,527,026 | 132,563,467 | |